Navigation Links
EUPROBIO 2008 Presentation to Highlight Latest Immune Research

Presentation to focus on a new dietary supplement resulting from years of study by leading research scientists in Russia, Ukraine and Bulgaria,

Del-Immune V

BOULDER, Colo., Oct. 6 /PRNewswire/ -- On Thursday, October 16, 2008 at the EUPROBIO 2008 Conference, an abstract entitled "Immune regulatory cytokines Del-Immune V(R) induction and its impact on cytotoxicity of natural killer cells" will be presented to physicians, researchers and educators. Attendees to the presentation will learn about the latest advancements in this field of research. After seeing the study abstract, conference organizers made last-minute changes to the conference schedule to include a presentation of this groundbreaking research.

The abstract is based on a recent study focusing on Del-Immune V(R), a new immunomodulator containing DNA and peptoglycan fragments of lactobacillus rhamnosus V. The study, which confirms that this formulation enhances immune function, was conducted in the Ukraine by several of Europe's foremost research scientists.

Among other findings, the study demonstrated that daily administration of Del-Immune V(R) within 5 days raised a level of circulating interferon up to 4.2+/-0.5 log2 u/ml (P <0.05) against 2.0+/-0.3 log2 u/ml of the controls. Interferons are the switches that help cells resist viral infection and provide the initial, crucial immune response to immune challenges. The results of this latest research demonstrate the immune modulator activity of Del-Immune V(R) and the potential value the dietary supplement may have in clinical situations.

Del-Immune V(R) is a dietary supplement containing a natural culture that starts with healthy bacteria originally found in unpasteurized milk. Unique technological processing of the Del-Immune V(R) formulation creates a natural immunostimulant. The study described above and other research indicates that Del-Immune V(R) could be beneficial in assisting the body in its natural role of protecting the body from germs, viruses and other bodily invaders.

Del-Immune V(R) dietary supplements are produced in the United States. Thousands of people take Del-Immune V(R) on a regular basis and doctors have reported positive results, including an enhanced resistance to cold and flu and a restorative effect on the immune system.

The EUPROBIO 2008 Conference will be held October 15-18, 2008 in Cracow, Poland at Auditorium Maximum.


Pamela Sichel

Pure Research Products, LLC


This release was issued through eReleases(TM). For more information, visit

SOURCE Pure Research Products, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):